Yoshiteru Takekita (Y Takekita)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2015-2023
Publications (10 Years): 4

Top Topics

Tyrosine Kinase

Placebo Controlled

Clinical Practice

Top Venues

International journal of molecular sciences

Translational psychiatry

Neuropsychopharmacology reports

This page only lists publications with an associated author ORCID identifier.

Publications

Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Daisuke Matsui, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Toshiyuki Shimizu, Yuji Murase, Yosuke Koshikawa, Masaki Kato, Toshihiko Kinoshita
Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data. Neuropsychopharmacology reports (2023)
Toshiya Funatsuki, Haruhiko Ogata, Hidetoshi Tahara, Akira Shimamoto, Yoshiteru Takekita, Yosuke Koshikawa, Shinpei Nonen, Koichiro Higasa, Toshihiko Kinoshita, Masaki Kato
Changes in Multiple microRNA Levels with Antidepressant Treatment Are Associated with Remission and Interact with Key Pathways: A Comprehensive microRNA Analysis. International journal of molecular sciences 24 (15) (2023)
Masaki Kato, Haruhiko Ogata, Hidetoshi Tahara, Akira Shimamoto, Yoshiteru Takekita, Yosuke Koshikawa, Keiichiro Nishida, Shinpei Nonen, Koichiro Higasa, Toshihiko Kinoshita
Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. International journal of molecular sciences 23 (7) (2022)
Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Naotaka Sunada, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Chikashi Takano, Tomoyo Yanagida, Yosuke Koshikawa, Minami Naito, Atsuko Yamamoto, Masaki Kato, Toshihiko Kinoshita
Divergence of dose-response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study. CNS spectrums (2021)
M Kato, A Serretti, S Nonen, Yoshiteru Takekita, M Wakeno, J Azuma, T Kinoshita
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Translational psychiatry 5 (2015)